Preclinical studies of STING agonists exemplified by MK-1454 have demonstrated strong cytokine induction and anti-tumor effects in syngeneic murine models, where pairing with PD-1 inhibition further enhanced tumor regression. This evidence concerns the gene STING1 and neoplasm.